US
CA
NZ
UK
AU
IND
Last update at 2025-05-16T16:42:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Amwell® to participate in upcoming investor conferences
Thu 24 Apr 25, 11:30 AMAmwell® to report first quarter 2025 operating results
Thu 17 Apr 25, 11:05 AMAmwell® makes grants to new employees under inducement plan
Fri 21 Feb 25, 02:22 PMAmwell® to report fourth quarter and full year 2024 operating results
Wed 29 Jan 25, 12:00 PM3 Tech Stocks That Could Grow Your Wealth
Fri 19 Jul 24, 12:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -269.73000M | -179.02600M | -225.79900M | -89.16900M | -52.31200M |
| Minority interest | 1.64M | 0.45M | 22.07M | 26.26M | 27.43M |
| Net income | -269.79400M | -173.65000M | -226.43800M | -88.36600M | -52.67400M |
| Selling general administrative | 146.35M | 94.62M | 166.25M | 54.21M | 37.22M |
| Selling and marketing expenses | 81.63M | 66.15M | 55.09M | 47.67M | 31.63M |
| Gross profit | 116.77M | 104.31M | 88.47M | 68.88M | 55.34M |
| Reconciled depreciation | 26.17M | 16.09M | 10.15M | 7.76M | 5.33M |
| Ebit | -275.85300M | -179.14600M | -227.43100M | -94.70400M | -55.10600M |
| Ebitda | -249.68600M | -163.05700M | -217.27800M | -86.94300M | -49.77600M |
| Depreciation and amortization | 26.17M | 16.09M | 10.15M | 7.76M | 5.33M |
| Non operating income net other | -2.27800M | -3.13200M | -2.18800M | - | - |
| Operating income | -275.85300M | -179.14600M | -227.43100M | -94.70400M | -55.10600M |
| Other operating expenses | 553.04M | 431.94M | 472.70M | 243.56M | 169.06M |
| Interest expense | 6.12M | 0.12M | 1.63M | 6.71M | 0.00000M |
| Tax provision | 0.06M | -5.37600M | 0.64M | -0.80300M | 0.00000M |
| Interest income | 6.12M | 0.12M | 1.63M | 5.54M | 2.79M |
| Net interest income | 6.12M | 0.12M | 1.63M | 5.54M | 2.79M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.06M | -5.37600M | 0.64M | -0.80300M | 2.79M |
| Total revenue | 277.19M | 252.79M | 245.26M | 148.86M | 113.95M |
| Total operating expenses | 392.62M | 283.46M | 315.91M | 163.59M | 110.45M |
| Cost of revenue | 160.42M | 148.47M | 156.79M | 79.98M | 58.61M |
| Total other income expense net | 6.12M | 0.12M | 1.63M | 5.54M | 2.79M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -272.07200M | -176.78200M | -228.62600M | -88.36600M | -52.31200M |
| Net income applicable to common shares | -270.42900M | -176.33400M | -224.43200M | -87.19000M | -52.67400M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 589.71M | 1217.56M | 1445.84M | 1376.65M | 499.88M |
| Intangible assets | 120.25M | 134.98M | 152.41M | 55.53M | 63.53M |
| Earning assets | - | - | - | - | - |
| Other current assets | 16.75M | 19.57M | 21.98M | 17.28M | 10.07M |
| Total liab | 109.52M | 133.71M | 184.96M | 130.45M | 780.75M |
| Total stockholder equity | 464.22M | 1063.88M | 1239.26M | 1224.13M | -307.12300M |
| Deferred long term liab | - | 3.39M | 2.03M | 1.33M | 1.64M |
| Other current liab | 35.41M | 54.26M | 58.71M | 42.13M | 27.35M |
| Common stock | 2.88M | 2.77M | 2.62M | 2.36M | 0.42M |
| Capital stock | 2.88M | 2.77M | 2.62M | 2.36M | 0.42M |
| Retained earnings | -1757.77800M | -1082.02800M | -811.28400M | -582.35900M | -357.92700M |
| Other liab | - | 7.86M | 28.64M | 8.17M | 11.21M |
| Good will | 0.00000M | 435.28M | 442.76M | 193.88M | 193.88M |
| Other assets | - | 6.16M | 4.54M | 10.12M | 4.33M |
| Cash | 372.04M | 538.55M | 746.42M | 941.62M | 137.67M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 93.80M | 114.06M | 141.63M | 120.98M | 106.58M |
| Current deferred revenue | 46.37M | 49.51M | 68.84M | 66.69M | 66.49M |
| Net debt | -360.25200M | -523.70200M | -729.80400M | -933.96300M | -124.27700M |
| Short term debt | 7.16M | 3.06M | 1.92M | 6.36M | 6.23M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 11.79M | 14.84M | 16.61M | 7.65M | 13.40M |
| Other stockholder equity | 2234.77M | 2160.11M | 2054.28M | 427.19M | 50.13M |
| Property plant equipment | - | 1.01M | 18.66M | 10.45M | 14.61M |
| Total current assets | 449.58M | 626.62M | 827.30M | 1113.29M | 223.53M |
| Long term investments | 1.18M | 0.00000M | 0.17M | 0.75M | 0.00000M |
| Net tangible assets | - | 493.62M | 644.09M | 974.73M | -564.53500M |
| Short term investments | - | - | 0.00000M | 99.96M | 39.95M |
| Net receivables | 54.15M | 58.37M | 51.38M | 45.30M | 32.73M |
| Long term debt | - | - | - | - | - |
| Inventory | 6.65M | 8.74M | 7.53M | 9.13M | 3.10M |
| Accounts payable | 4.86M | 7.24M | 12.16M | 5.80M | 6.50M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 19.97M | 21.62M | 22.07M | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -15.65000M | -16.96900M | -6.35300M | 0.30M | 0.25M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 2.77M | 2.62M | 2.36M | 0.42M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -1082.02800M | -811.28400M | -582.35900M | - |
| Treasury stock | - | - | - | -37.56800M | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 7.67M | 6.16M | 2.52M | 1.43M | 4.33M |
| Deferred long term asset charges | - | 3.39M | 2.03M | 1.33M | - |
| Non current assets total | 140.12M | 590.94M | 618.54M | 263.36M | 276.35M |
| Capital lease obligations | 11.79M | 14.84M | 16.61M | 7.65M | 13.40M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -11.63000M | 97.45M | -66.75700M | 120.00M | -245.93300M |
| Change to liabilities | 4.16M | -3.82300M | -2.88100M | -14.99100M | -17.75900M |
| Total cashflows from investing activities | -11.63000M | -59.63300M | -66.75700M | 120.00M | -245.93300M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -3.61200M | 5.75M | 983.12M | 46.64M | 278.18M |
| Change to operating activities | 5.77M | -24.97800M | 4.67M | 0.26M | -1.11000M |
| Net income | -272.07200M | -176.78200M | -228.62600M | -88.36600M | -52.31200M |
| Change in cash | -207.87000M | -195.50000M | 803.89M | 84.75M | -41.75800M |
| Begin period cash flow | 747.21M | 942.71M | 138.82M | 54.07M | 95.83M |
| End period cash flow | 539.34M | 747.21M | 942.71M | 138.82M | 54.07M |
| Total cash from operating activities | -192.32300M | -141.53700M | -112.46400M | -81.89200M | -74.00600M |
| Issuance of capital stock | 0.00000M | 0.00000M | 1018.04M | 45.76M | 280.44M |
| Depreciation | 26.17M | 16.09M | 10.15M | 7.76M | 5.33M |
| Other cashflows from investing activities | -10.15500M | -156.52600M | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -1.20700M | 1.60M | -6.02400M | -0.59200M | 1.57M |
| Change to account receivables | -8.14000M | -0.51200M | -14.21200M | 0.80M | -19.47100M |
| Sale purchase of stock | -0.36000M | -15.03800M | -37.56800M | -0.15800M | -2.89800M |
| Other cashflows from financing activities | -8.99200M | -123.31500M | 148.65M | 46.80M | 281.08M |
| Change to netincome | 68.23M | 43.72M | 118.00M | 10.29M | 8.79M |
| Capital expenditures | 10.45M | 0.56M | 3.32M | 1.34M | 1.91M |
| Change receivables | -8.14000M | -0.51200M | -14.21200M | - | - |
| Cash flows other operating | -9.46300M | -11.80100M | -7.88200M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -207.56500M | -195.41600M | 803.89M | - | - |
| Change in working capital | -28.09600M | -27.71500M | -18.44500M | -14.52000M | -36.77100M |
| Stock based compensation | 67.67M | 43.81M | 118.36M | 12.13M | 7.67M |
| Other non cash items | 16.53M | 9.31M | 2.26M | 2.49M | 1.19M |
| Free cash flow | -202.77000M | -142.09600M | -115.78200M | -83.23000M | -75.91700M |
Sector: Healthcare Industry: Health Information Services
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AMWL American Well Corp |
-0.11 1.47% | 7.37 | - | - | 0.59 | 0.43 | 0.73 | -0.8154 |
| GEHC GE HealthCare Technologies Inc. |
0.03 0.04% | 72.94 | 22.91 | 20.12 | 2.01 | 5.52 | 2.39 | 13.30 |
| VEEV Veeva Systems Inc Class A |
0.48 0.20% | 242.08 | 54.61 | 33.22 | 12.83 | 6.73 | 11.14 | 58.84 |
| MTHRF M3 Inc |
- -% | 12.95 | 29.72 | 25.00 | 0.05 | 4.38 | 0.04 | 0.12 |
| MTHRY M3 Inc |
0.07 1.05% | 6.72 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
75 State Street, Boston, MA, United States, 02109
| Name | Title | Year Born |
|---|---|---|
| Dr. Ido Schoenberg M.D. | Chairman & Co-CEO | 1965 |
| Dr. Roy Schoenberg M.D., M.P.H., MPH | Pres, Co-CEO & Director | 1969 |
| Mr. Robert Shepardson | CFO & Exec. VP | 1965 |
| Mr. Kurt Knight | Exec. VP & COO | 1979 |
| Ms. Phyllis I. Gotlib | Exec. VP & Pres of International | 1958 |
| Mr. Paul Francis McNeice | VP of Accounting | 1977 |
| Mr. Serkan Kutan | Chief Technology Officer | 1977 |
| Mr. Tim Conway | Chief Information Officer | NA |
| Mr. Bradford F. Gay | Sr. VP & Gen. Counsel | 1977 |
| Ms. Susan Worthy | Chief Marketing Officer | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...